logo-loader
viewCytoDyn Inc.

CytoDyn files for fast-track designation for leronlimab in breast cancer treatment

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive Investors the biotechnology company filed an application with the FDA seeking fast-track designation for its injectable antibody leronlimab for patients with metastatic-triple negative breast cancer.

Pourhassan also commented on its HIV indication for leronlimab, commenting there is a large biological manufacturer willing to produce 'half a billion dollars worth' of the company's product by the end of 2020.

Quick facts: CytoDyn Inc.

Price: 4.73 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.46 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn CEO calls Citron Research report 'false', updates on coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan addressed the recent report published by short seller Citron Research, entitled "SEC must immediately halt this stock promotion scheme." What's more, Pourhassan talked about the firm's two US-based coronavirus clinical trials, and its anticipated...

1 week, 4 days ago

2 min read